Vyant Bio, Inc. 4/A SEC Filings

Filed On	Filing
29 Dec 2021	Form 4/A: LaFrence Andrew D.c., Chief Financial Officer Bought 5,000 shares ($10K)
25 Aug 2021	Form 4/A: Roberts John A, Chief Executive Officer Holds 24,401 shares of Common Stock, $0.0001 par value
13 Jul 2021	Form 4/A: LaFrence Andrew D.c., Chief Financial Officer Acquired 56,117 shares (Other Transaction)
13 Jul 2021	Form 4/A: Hansen Paul R., Director Acquired 662,858 shares (Other Transaction)
13 Jul 2021	Form 4/A: Yeh Yung-Ping, Director Acquired 1,326,625 shares (Other Transaction)
01 Jul 2021	Form 4/A: Boehm Marcus, Director Acquired 93,786 shares (Other Transaction) · Gave 78,263 shares as a gift · Acquired 78,263 shares (Gift) · 4 more
18 Aug 2017	Form 4/A: Pappajohn John, Director Bought 66,185 shares ($214K) · Bought 20,000 shares ($65.6K)
19 Jul 2016	Form 4/A: Pappajohn John, Director Bought 317,820 shares
26 May 2016	Form 4/A: Pappajohn John, Director Bought 2,500 shares ($22.4K) · Bought 2,500 shares ($25.6K)
14 Jul 2015	Form 4/A: Hepburn Steven, VP of Biopharma Marketing Received 3,000 shares as a grant or award · Granted 15,000 Stock Option (right to buy)
11 Jun 2014	Form 4/A: Prendergast Franklyn G, Director Granted 10,000 Stock Option (right to buy)
11 Jun 2014	Form 4/A: Cannon Edmund, Director Granted 10,000 Stock Option (right to buy)
11 Jun 2014	Form 4/A: Brownlie Keith L, Director Granted 10,000 Stock Option (right to buy)

Comments